Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MN › Rochester › NPI 1083249577
Lab

Mayo Clinic

Mayo Clinic was paid $15.25M by Medicaid between Oct 2020 and Dec 2024, across 301 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 19% of everything it billed.

33Billing provider infoMAYO CLINIC
ROCHESTER, MN 55905
33aNPI1083249577assigned 03/05/2020
33bProvider typeClinical Medical Laboratory
28Total paid$15.25M
24GClaims942,685
24DCodes billed301
24AFirst – last monthOct 2020 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Minnesota

Rank by total paid#5 of 69
Median peer was paid$48K
This provider vs. median316×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official DAHLEN, DENNIS controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$250K$500K$750K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
202044,653$925K
2021227,270$3.97M
2022229,289$3.86M
2023243,608$3.51M
2024incomplete197,865$2.98M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 19% 42,756 39,129 $2.92M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 4.9% 35,895 33,007 $742K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 4.5% 4,910 4,666 $680K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 3.0% 72,209 62,748 $460K
84443 Thyroid stimulating hormone (TSH) 3.0% 31,931 30,805 $451K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 2.4% 14,587 14,352 $370K
87631 2.1% 2,419 2,353 $327K
80053 Comprehensive metabolic panel 2.1% 36,529 32,518 $320K
87507 2.0% 796 785 $298K
86832 1.9% 1,336 1,266 $283K
86833 1.8% 1,334 1,263 $281K
82728 1.7% 20,996 20,546 $252K
289 more codes
80061 Lipid panel 1.6% 21,518 $247K
36415 Collection of venous blood by venipuncture 1.6% 57,248 $244K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1.6% 1,303 $236K
83036 Hemoglobin; glycosylated (A1C) 1.4% 25,712 $213K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 1.3% 5,921 $204K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 1.3% 5,921 $204K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) 1.3% 4,504 $193K
88305 Level IV - Surgical pathology, gross and microscopic examination 1.1% 2,108 $175K
80048 Basic metabolic panel (calcium, ionized) 1.1% 24,944 $170K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1.1% 2,887 $165K
86480 1.1% 2,738 $161K
86140 1.0% 15,836 $157K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 5,686 $138K
83880 <1% 4,196 $137K
86364 <1% 3,292 $129K
83970 <1% 3,804 $122K
81376 <1% 484 $115K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 1,206 $115K
83935 <1% 19,737 $111K
82784 <1% 7,662 $106K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 2,882 $105K
83615 <1% 3,526 $101K
82607 <1% 7,589 $99K
82565 <1% 22,885 $90K
85027 <1% 15,235 $85K
87086 Culture, bacterial; quantitative colony count, urine <1% 12,284 $85K
88185 <1% 524 $84K
86235 <1% 986 $78K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 869 $78K
80197 <1% 7,326 $77K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 2,234 $75K
84439 <1% 8,944 $71K
83735 <1% 12,409 $67K
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 3,211 $65K
86780 <1% 4,950 $65K
84403 <1% 2,756 $64K
83013 <1% 928 $63K
81001 <1% 21,774 $57K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 1,162 $57K
84450 <1% 13,574 $56K
87536 <1% 733 $56K
82570 <1% 12,477 $55K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 1,170 $55K
82542 <1% 1,978 $53K
85610 <1% 15,480 $53K
84460 <1% 11,950 $53K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 1,543 $53K
83520 <1% 2,764 $52K
84702 <1% 3,419 $49K
87799 <1% 1,562 $48K
82533 <1% 3,210 $47K
80050 General health panel <1% 1,111 $45K
82248 <1% 9,995 $44K
86850 <1% 4,840 $43K
82610 <1% 2,991 $43K
87340 <1% 4,334 $42K
87077 <1% 4,995 $42K
83550 <1% 5,368 $41K
83516 <1% 3,944 $41K
82947 <1% 11,839 $40K
87497 <1% 1,007 $40K
87999 <1% 149 $39K
84153 <1% 2,221 $38K
82043 <1% 7,219 $35K
83655 <1% 2,230 $35K
88184 <1% 543 $33K
82670 <1% 1,277 $33K
88342 <1% 364 $32K
87186 <1% 3,874 $32K
84100 <1% 8,347 $32K
82746 <1% 2,510 $32K
83540 <1% 5,582 $31K
86360 <1% 823 $31K
86376 <1% 2,446 $31K
86038 <1% 2,811 $31K
88112 <1% 507 $30K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 397 $30K
86200 <1% 2,478 $29K
84075 <1% 6,895 $28K
84132 <1% 7,942 $28K
86706 <1% 2,754 $28K
86359 <1% 863 $26K
86704 <1% 2,282 $26K
84410 <1% 546 $25K
84402 <1% 1,077 $25K
80069 <1% 3,590 $25K
82310 <1% 6,109 $24K
86923 <1% 334 $24K
85652 <1% 9,835 $23K
83521 <1% 1,606 $23K
86160 <1% 1,194 $23K
82627 <1% 1,075 $23K
82247 <1% 5,358 $22K
86803 <1% 1,611 $21K
84165 <1% 2,315 $21K
87517 <1% 482 $21K
84295 <1% 5,764 $21K
83001 <1% 1,214 $21K
84146 <1% 1,119 $20K
83921 <1% 1,106 $20K
87522 Neg quan hep c or qual rna <1% 507 $19K
82105 <1% 1,183 $18K
84550 <1% 4,882 $18K
80076 <1% 2,403 $18K
81528 Oncology (colorectal) screening, quantitative real-time target and signal amplification <1% 60 $17K
86147 <1% 411 $16K
86355 <1% 551 $16K
86665 <1% 928 $16K
0077U <1% 2,380 $16K
81513 <1% 104 $15K
83002 <1% 882 $15K
82024 <1% 395 $14K
85730 <1% 2,557 $13K
82040 <1% 3,413 $13K
82550 <1% 2,243 $13K
86003 <1% 286 $13K
87102 <1% 1,606 $12K
86255 <1% 447 $12K
88142 <1% 631 $12K
86787 <1% 975 $12K
86900 <1% 4,468 $12K
86901 <1% 4,474 $12K
84305 <1% 653 $12K
84484 <1% 1,190 $12K
0097U <1% 108 $12K
86146 <1% 310 $12K
87205 <1% 2,940 $12K
83021 <1% 646 $11K
87103 <1% 369 $11K
88341 <1% 42 $11K
86357 <1% 361 $10K
84520 <1% 3,283 $10K
86762 <1% 731 $10K
86225 <1% 870 $10K
82378 <1% 611 $10K
86431 <1% 1,862 $10K
83690 <1% 1,580 $10K
84155 <1% 3,113 $9K
84630 <1% 858 $9K
83020 <1% 739 $9K
86341 <1% 259 $9K
87081 <1% 1,283 $9K
83993 <1% 508 $9K
87070 <1% 1,055 $8K
82507 <1% 361 $8K
82977 <1% 1,221 $8K
84446 <1% 592 $8K
86039 <1% 737 $7K
84156 <1% 2,356 $7K
85379 <1% 798 $7K
82785 <1% 462 $7K
84590 <1% 633 $7K
86664 <1% 465 $7K
84207 <1% 255 $7K
86644 <1% 465 $7K
87206 <1% 1,299 $7K
86645 <1% 384 $6K
86301 <1% 344 $6K
82140 <1% 548 $6K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 44 $6K
82525 <1% 524 $6K
81479 Unlisted molecular pathology procedure <1% 13 $6K
86162 <1% 315 $6K
81050 <1% 2,027 $6K
87040 <1% 628 $6K
84425 <1% 284 $6K
80180 <1% 520 $5K
84238 <1% 167 $5K
82107 <1% 99 $5K
81370 <1% 14 $5K
86304 <1% 268 $5K
84134 <1% 363 $5K
82088 <1% 135 $5K
80195 <1% 448 $5K
85613 <1% 459 $5K
83945 <1% 406 $5K
86708 <1% 407 $5K
85390 <1% 367 $5K
84080 <1% 391 $4K
83498 <1% 188 $4K
80164 <1% 439 $4K
82103 <1% 327 $4K
86800 <1% 283 $4K
83883 <1% 224 $4K
80051 <1% 689 $4K
80177 <1% 380 $4K
85046 <1% 712 $4K
85045 <1% 1,002 $4K
82652 <1% 108 $4K
86381 <1% 61 $4K
84166 <1% 231 $3K
84300 <1% 817 $3K
83718 <1% 658 $3K
87529 <1% 100 $3K
85397 <1% 110 $3K
86696 <1% 166 $3K
87481 <1% 88 $3K
85384 <1% 339 $3K
84244 <1% 149 $3K
87106 <1% 268 $3K
84480 <1% 204 $3K
83835 <1% 172 $3K
82390 <1% 255 $3K
82465 <1% 836 $2K
84681 <1% 149 $2K
82340 <1% 534 $2K
84432 <1% 170 $2K
86141 <1% 222 $2K
82150 <1% 472 $2K
81025 <1% 278 $2K
86709 <1% 209 $2K
86695 <1% 166 $2K
81003 <1% 1,453 $2K
87493 <1% 71 $2K
85246 <1% 101 $2K
80165 <1% 244 $2K
84560 <1% 489 $2K
85240 <1% 125 $2K
86356 <1% 53 $2K
82157 <1% 68 $2K
80175 <1% 200 $2K
86777 <1% 129 $2K
83986 <1% 654 $2K
86765 <1% 153 $2K
82436 <1% 389 $2K
85670 <1% 370 $2K
84105 <1% 375 $2K
86618 <1% 108 $2K
86769 <1% 44 $2K
84133 <1% 445 $2K
83010 <1% 150 $2K
81240 <1% 27 $2K
84392 <1% 347 $2K
86870 <1% 28 $1K
84126 <1% 44 $1K
84540 <1% 311 $1K
86015 <1% 109 $1K
84478 <1% 189 $1K
87116 <1% 104 $1K
G0476 Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test <1% 40 $1K
86735 <1% 85 $1K
86335 <1% 40 $1K
G0475 Hiv antigen/antibody, combination assay, screening <1% 95 $983.05
86592 <1% 238 $956.72
82374 <1% 232 $937.98
85018 <1% 392 $892.94
83014 <1% 105 $824.71
82985 <1% 65 $821.38
82232 <1% 57 $728.96
82085 <1% 78 $706.95
87209 <1% 35 $661.09
83695 <1% 52 $600.70
86698 <1% 26 $589.84
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 72 $583.90
86682 <1% 41 $539.36
82948 <1% 192 $529.99
86812 <1% 24 $522.53
85007 <1% 140 $469.49
82787 <1% 30 $464.97
85250 <1% 25 $461.41
89051 <1% 93 $421.26
80178 <1% 61 $417.54
87563 <1% 12 $408.72
85306 <1% 29 $397.06
82330 <1% 26 $357.74
85303 <1% 27 $343.79
82384 <1% 12 $340.79
87177 <1% 34 $318.15
82575 <1% 40 $311.88
87015 <1% 44 $299.33
83605 <1% 26 $286.42
85300 <1% 26 $280.84
82010 <1% 38 $277.05
87641 <1% 12 $264.85
86337 <1% 13 $255.33
87075 <1% 24 $241.24
87385 <1% 12 $221.87
84481 <1% 13 $211.66
85307 <1% 14 $202.07
82104 <1% 14 $201.53
84466 <1% 13 $179.59
82951 <1% 13 $178.51
82668 <1% 12 $153.87
82164 <1% 13 $137.49
82435 <1% 27 $101.01
84436 <1% 14 $87.90
83930 <1% 14 $69.73
82952 <1% 13 $54.41
0753T 0% 178 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDAHLEN, DENNIS (CFO)
Parent organizationMAYO CLINIC
Same official

Other billing entities under DAHLEN, DENNIS

Full network →
ProviderLocationPaid
Mayo ClinicRochester, MN$74.39M
Mayo Clinic Hospital-RochesterRochester, MN$11.46M
Mayo Foundation for Medical Education & ResearchRochester, MN$2.83M
Mayo Clinic Hospital-RochesterOnalaska, WI$832K
Mayo Clinic Hospital-RochesterFairmont, MN$682K
Mayo Foundation for Medical Education & ResearchRochester, MN$320K
Mayo Clinic Hospital-RochesterRochester, MN$193K
Mayo Clinic Hospital-RochesterRochester, MN$181K
Mayo Clinic Hospital-RochesterAlbert Lea, MN$52K
Mayo Clinic Hospital-RochesterOwatonna, MN$15K
Mayo Clinic Hospital-RochesterDecorah, IA$423.45
Mayo ClinicRochester, MN$0.00

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.